Blog
RSS FeedPosted by Michael Wonder on 16 Sep 2021
PHARMAC funds tocilizumab to treat cases of COVID-19
16 September 2021 - PHARMAC is widening funded access to tocilizumab, an immunosuppressive drug used mainly to treat arthritis, to treat ...
Posted by Michael Wonder on 16 Sep 2021
PHARMAC funds new treatment for rheumatoid arthritis to support people impacted by tocilizumab stock shortage
16 September 2021 - PHARMAC has funded upadacitinib tablets as an alternative treatment for New Zealanders with severe rheumatoid arthritis, ...
Posted by Michael Wonder on 12 Sep 2021
NHS lung cancer patients in England get early access to ‘breakthrough’ cancer drug
10 September 2021 - The MHRA has approved a first-of-its-kind cancer drug – capable of targeting a gene mutation that ...
Posted by Michael Wonder on 09 Sep 2021
Insurance benefits for Pfizer’s heart drug Vyndamax uncertain
9 September 2021 - Pfizer’s Vyndamax (tafamidis), a treatment for transthyretin amyloid cardiomyopathy, got in the European Society of Cardiology’s ...
Posted by Michael Wonder on 09 Sep 2021
Consumers to have more say on medicine access issues
7 September 2021 - Consumer involvement in Australia’s medicines choices has been further strengthened under a new strategic agreement Medicines ...
Posted by Michael Wonder on 09 Sep 2021
MSD Australia endorses new medicines strategic agreement
8 September 2021 - MSD Australia has today welcomed the signing of a new Medicines Strategic Agreement between Medicines Australia ...
Posted by Michael Wonder on 08 Sep 2021
Withdrawals from pharmaceutical benefits on 1 October 2021
8 September 2021 - Suboxone is among the medicines that will be withdrawn from the drug benefits at the companies' ...
Posted by Michael Wonder on 07 Sep 2021
Landmark new medicines agreements to bring significant benefits for Australian patients
7 September 2021 - Australians will have more affordable, improved and guaranteed access to medicines under landmark long-term strategic agreements between ...
Posted by Michael Wonder on 07 Sep 2021
New strategic agreements with the medicines industry
7 September 2021 - The Australian Government has entered into new strategic agreements with Medicines Australia and the Generic and ...
Posted by Michael Wonder on 06 Sep 2021
Leap forward for patients accessing medicines
7 September 2021 - Medicines Australia has secured a 5 year strategic agreement with the Federal Government, centered on earlier ...
Posted by Michael Wonder on 06 Sep 2021
New treatment option for schizophrenia Reagila listed on PBS
6 September 2021 - Adults living with schizophrenia will have access to a new treatment option with Reagila (cariprazine), reimbursed ...
Posted by Michael Wonder on 02 Sep 2021
Patients in the Netherlands wait 1.5 years for access to new medicines
2 September 2021 - Patients in the Netherlands have to wait an average of 510 days for access to a new ...
Posted by Michael Wonder on 02 Sep 2021
CAR-T therapy Kymriah fails to get insurance benefits
2 September 2021 - The first CAR-T therapy, Kymriah (ingredient: tisagenlecleucel), failed to pass the review of a panel at ...
Posted by Michael Wonder on 31 Aug 2021
Price relief as epilepsy drug PBS listed
1 September 2021 - Australian epilepsy sufferers will now be reimbursed for a drug that reduces uncontrolled seizures, as a ...
Posted by Michael Wonder on 31 Aug 2021
Schedule of Pharmaceutical Benefits - 1 September 2021 update
1 September 2021 - The September 2021 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...